Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2021 and 2022.
-
Legal situation KBO
Opening faillissement according to the CBE.
Financials
Financial year 2022
Mithra Pharmaceuticals from Liège, company number BE0466526646, closed financial year 2022 with a result of € -42.5 million after tax. For that financial year Mithra Pharmaceuticals recorded revenue of € 23.3 million and equity of € 290.2 million. Compared with financial year 2021, the result moved from € -883,845 to € -42.5 million. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 12, 2023.
€ 290.2 million
▲ 16% vs 2021
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -42.5 million
▼ 4713 % more loss than in 2021
Profit after tax over the fiscal year.
€ 27.6 million
▲ 62% vs 2021
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -163.5 million.
People and assets in 2022
40
▼ 1 vs 2021
Average over the fiscal year, from the social balance sheet.
€ 4 million
▲ 25% vs 2021
€ 100,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 428,113
▼ 17% vs 2021
Book value of vehicles, furniture and equipment.
Debts at end 2022
€ 181.6 million
▲ 8% vs 2021
€ 11.1 million is repaid this year. At this pace the long-term loan is gone in ≈ 14 years.
€ 2.2 million
▲ 29% vs 2021
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 42 days on average.
€ 2.7 million
▲ € 2.4 million vs 2021
Taxes, VAT and social contributions still to pay.
| 2021 | 2022 | Change 2021 → 2022 | |
|---|---|---|---|
| Revenue | € 15,677,471 | € 23,277,970 | ▲ 48% |
| Profit after taxes | € -883,845 | € -42,541,966 | ▼ € 41.7 million |
| Equity | € 249,881,614 | € 290,234,227 | ▲ 16% |
| Total debts | € 209,923,403 | € 223,148,482 | ▲ 6% |
| Cash | € 17,042,644 | € 27,599,280 | ▲ 62% |
| Land & buildings | € 857,062 | € 774,983 | ▼ 10% |
| Retained profit | € -120,961,862 | € -163,503,828 | ▼ € 42.5 million |
| Bank debt | € 167,450,786 | € 181,632,754 | ▲ 8% |
| Balance sheet total | € 460,071,017 | € 513,648,709 | ▲ 12% |
| Employees (FTE) | 41 | 40 | ▼ 1 |
By revenue, Mithra Pharmaceuticals ranks 6th of 9 companies with main activity “Vervaardiging van geneesmiddelen” in the province of Liège that publish figures (fiscal year 2022).
Key figures of Mithra Pharmaceuticals, fiscal years 2021 to 2022, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2023 has not been filed yet; it was expected before 31 July 2024.
Ask about Mithra Pharmaceuticals the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to Mithra Pharmaceuticals?
What happened at Mithra Pharmaceuticals in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
Mithra Pharmaceuticals is active according to the CBE. Legal situation: Opening faillissement.
- New annual accounts for financial year 2022: loss of € 42.5 million. Source: NBB ↗
- Eva Consulting SRL stepped down as director. NBB
- An Cloet stepped down as director. NBB
- SELVA LUXEMBOURG SA stepped down as director. NBB
- NOSHAQ SA stepped down as director. NBB
- Patricia Van Dijck stepped down as director. NBB
- AMEL TOUNSI stepped down as director. NBB
- Liesbeth Weynants stepped down as director. NBB
In short
From € 883,845 loss in 2021 to € 42.5 million loss in 2022.
Paid € 2.6 million in corporate taxes since 2021.
Pays suppliers within 42 days on average.
Management
It owns 100% of Wecare Pharmaceuticals, 100% of NEURALIS, 100% of Estetra, 100% of Mithra Letzebuerg, 99% of Mithra CDMO and 99% of Novalon itself.
Directors
According to the 2022 annual accounts
Director · represented by Jean Michel Foidart
since 2021 · until 2023
An Cloet
Director
since 2021 · until 2023
SELVA LUXEMBOURG SA
Director · represented by Christian Moretti
since 2019 · until 2023
Director · represented by Gaetan Servais
Also active at: FRANKI, Iso - Calor, DARDENNE, DAO, Bureau d'Etudes Pierre Berger, SOGECOM, NOSHAQ IMMO, GABRIEL +60 more
since 2021 · until 2023
Director · represented by Ajit Shetty
Also active at: SOUDAL HOLDING, reMYND, Newton Biocapital I, pricaf privée de droit belge, REJUVENATE BIOMED, Newton Biocapital II
since 2021 · until 2022
Patricia Van Dijck
Director
since 2019 · until 2023
since 2021 · until 2023
Liesbeth Weynants
Director
since 2021 · until 2023
Director · represented by Erik Van den Eynden
Also active at: NEDCO, Immo V.V.L. Leuven, IMMOCOR, GILBO, LES FOUGERES, IMMOGRADA, HANSIMMO, ODEBRECHT +17 more
since 2021 · until 2023
since 2021 · until 2023
Director · represented by François Fornieri
Also active at: LE BOCHOLTZ, VITAMINES EVENTS, GUSTA SPRL, ARDENTIA IMMO, IMMO LIEGE PERRON, VIAE, EOLE RACING EVENTS
since 2021 · until 2022
Establishments
Establishment units
Physical locations of this company
Rue Saint-Georges 5
4000 Liège
Rue de l'Expansion 57
4400 Flémalle
Active since 26 June 2017
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in the province of Liège
Same main activity (Vervaardiging van geneesmiddelen), 14 active companies in the province of Liège, largest first.
€ 96.4 million revenue · 2025 · Verviers
€ 76.2 million revenue · 2025 · Grâce-Hollogne
€ 66.4 million revenue · 2025 · Liège
€ 35 million revenue · 2025 · Sankt Vith
€ 26.7 million revenue · 2022 · Liège
€ 5.5 million gross margin · 2025 · Liège
Details
- Company number
- 0466.526.646
- VAT number
- BE 0466.526.646
- Registered office
- Rue Saint-Georges 5, 4000 Liège
- Names & denominations
- Mithra Pharmaceuticals
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Opening faillissement
- Start date
- 13 July 1999
- Peppol
- Not registered
- Activities · NACE
Vervaardiging van geneesmiddelen
Groothandel in andere consumentenartikelen, neg
Overige groothandel in consumentenartikelen, n.e.g.